Late-stage trial data for Roche's drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy.
Teresa Zimmers, professor of cell, developmental and cancer biology at the Oregon Health & Sciences University School of Medicine, at 12:55 p.m. Wednesday, Jan. 29, on Zoom.